

# Adriana Eramo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2784794/publications.pdf>

Version: 2024-02-01

50  
papers

4,892  
citations

147801

31  
h-index

254184

43  
g-index

50  
all docs

50  
docs citations

50  
times ranked

7923  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ex Vivo Irradiation of Lung Cancer Stem Cells Identifies the Lowest Therapeutic Dose Needed for Tumor Growth Arrest and Mass Reduction In Vivo. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	2
2	Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches. <i>Molecules</i> , 2021, 26, 3619.	3.8	6
3	Therotyping cystic fibrosis <i>in vitro</i> in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells. <i>European Respiratory Journal</i> , 2021, 58, 2100908.	6.7	39
4	A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. <i>Cell Death and Disease</i> , 2019, 10, 529.	6.3	37
5	A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 373.	8.6	27
6	Theophylline induces differentiation and modulates cytoskeleton dynamics and cytokines secretion in human melanoma-initiating cells. <i>Life Sciences</i> , 2019, 230, 121-131.	4.3	14
7	Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth. <i>Cancer Letters</i> , 2019, 440-441, 23-34.	7.2	17
8	Conditionally reprogrammed cells (CRC) methodology does not allow the <i>in vitro</i> expansion of patient-derived primary and metastatic lung cancer cells. <i>International Journal of Cancer</i> , 2018, 143, 88-99.	5.1	22
9	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 140.	8.6	27
10	Abstract 2670: Natural compound tetrocarcin-A downregulates junctional adhesion molecule-A in conjunction with $\beta$ -catenin, her2 and inhibitor of apoptosis proteins and inhibits tumor cell growth. , 2018, , .		0
11	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	3.3	44
12	Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma. <i>Oncogene</i> , 2017, 36, 4641-4652.	5.9	86
13	Lipid Storage and Autophagy in Melanoma Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1271.	4.1	35
14	Resistance of papillary thyroid cancer stem cells to chemotherapy. <i>Oncology Letters</i> , 2016, 12, 687-691.	1.8	28
15	Wharton's jelly mesenchymal stromal cells have contrasting effects on proliferation and phenotype of cancer stem cells from different subtypes of lung cancer. <i>Experimental Cell Research</i> , 2016, 345, 190-198.	2.6	27
16	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. <i>Oncotarget</i> , 2016, 7, 11332-11348.	1.8	49
17	Abstract 2484: Non-canonical Hedgehog/Gli1 signaling drives lung adenocarcinoma stem cells survival and its targeting inhibits CSC-derived tumors. , 2016, , .		0
18	Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells. <i>European Journal of Pharmacology</i> , 2015, 762, 283-292.	3.5	43

#	ARTICLE	IF	CITATIONS
19	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. <i>Cell Death and Disease</i> , 2015, 6, e1850-e1850.	6.3	42
20	Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. <i>Oncotarget</i> , 2015, 6, 16926-16938.	1.8	28
21	Abstract 2324: The histone acetyltransferase inhibitor CPTH6 selectively targets lung cancer stem-like cells. , 2015, , .		0
22	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. <i>Molecular Cancer</i> , 2014, 13, 230.	19.2	51
23	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , 2014, 21, 1877-1888.	11.2	90
24	Abstract 1684: Histone deacetylase inhibition enhances Pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer models. , 2014, , .		0
25	Abstract 803: A vertical combination strategy hitting multiple steps along the MAPK cascade: Molecular mechanisms of action and putative genetic determinants of synergism. , 2014, , .		0
26	Abstract 2618: PTEN loss as a putative biomarker of synergistic growth inhibitory activity of combined MEK/ERK and PI3K/mTOR pathway blockade. , 2014, , .		0
27	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 91.	8.6	18
28	Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas. <i>International Journal of Oncology</i> , 2013, 43, 95-102.	3.3	40
29	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. <i>Cell Death and Differentiation</i> , 2012, 19, 768-778.	11.2	157
30	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	3.9	54
31	EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential. <i>PLoS ONE</i> , 2012, 7, e46891.	2.5	36
32	Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. <i>Journal of Neuroinflammation</i> , 2011, 8, 32.	7.2	102
33	Lung cancer stem cells: tools and targets to fight lung cancer. <i>Oncogene</i> , 2010, 29, 4625-4635.	5.9	125
34	Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4299-4311.	7.0	153
35	The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. <i>Oncogene</i> , 2009, 28, 3586-3596.	5.9	74
36	Small-Molecule XIAP Inhibitors Enhance $\hat{3}$ -Irradiation-Induced Apoptosis in Glioblastoma. <i>Neoplasia</i> , 2009, 11, 743-W9.	5.3	98

#	ARTICLE	IF	CITATIONS
37	Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. <i>Cell Research</i> , 2008, 18, 664-676.	12.0	34
38	Identification and expansion of the tumorigenic lung cancer stem cell population. <i>Cell Death and Differentiation</i> , 2008, 15, 504-514.	11.2	1,511
39	MicroRNAs Impair MET-Mediated Invasive Growth. <i>Cancer Research</i> , 2008, 68, 10128-10136.	0.9	168
40	Proteasome Inhibitors Synergize with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Anaplastic Thyroid Carcinoma Cell Death. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1938-1942.	3.6	48
41	Chemotherapy resistance of glioblastoma stem cells. <i>Cell Death and Differentiation</i> , 2006, 13, 1238-1241.	11.2	578
42	The PU.1 transcription factor induces cyclin D2 expression in U937 cells. <i>Leukemia</i> , 2006, 20, 2208-2210.	7.2	4
43	Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Destruction. <i>Cancer Research</i> , 2005, 65, 11469-11477.	0.9	81
44	CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. <i>European Journal of Immunology</i> , 2004, 34, 1930-1940.	2.9	95
45	Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. <i>Cell Death and Differentiation</i> , 2003, 10, 905-913.	11.2	45
46	Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor. <i>Journal of Biological Chemistry</i> , 1999, 274, 38241-38250.	3.4	148
47	Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. <i>Nature</i> , 1999, 401, 489-493.	27.8	369
48	Caspase activation without death. <i>Cell Death and Differentiation</i> , 1999, 6, 1075-1080.	11.2	109
49	Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. <i>European Journal of Immunology</i> , 1998, 28, 57-69.	2.9	103
50	Fas Splicing Variants and their Effect on Apoptosis. <i>Advances in Experimental Medicine and Biology</i> , 1996, 406, 125-134.	1.6	28